Michele C. Azada

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 688 citations

Phase 1/2, Neuro-oncology, Dose-finding Portion +9

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib

Sai‐Hong Ignatius Ou, Michele C. Azada, David Hsiang et al. · Journal of Thoracic Oncology · 2014 · 168 citations · Full text

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib

Sai‐Hong Ignatius Ou, Samuel J. Klempner, Joel Greenbowe et al. · Journal of Thoracic Oncology · 2014 · 94 citations · Full text

Non–small-cell Lung Cancer, Alk-rearranged Nsclc Patients, Medicine +9

Heart rate decrease during crizotinib treatment and potential correlation to clinical response

Sai‐Hong Ignatius Ou, Wilson P. Tong, Michele C. Azada et al. · Cancer · 2013 · 83 citations · Full text

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib

Sai‐Hong Ignatius Ou, Joel Greenbowe, Ziad U. Khan et al. · Lung Cancer · 2015 · 80 citations

Progressive Disease, Genetic Disorder, Genetics +8